Nurse Practitioner, Family · Orlando, FL
NPI
1154860138
Since 2017
Specialty
Nurse Practitioner, Family
Code 363LF0000X
Group practices
3
Medicare group memberships
Hospitals
2
Hospital affiliations
265 E Rollins St Ste 10000
Orlando, FL, 32804
Phone (407) 303-9921
Groups this clinician bills Medicare through
Medicare paid, 2024
$14K
185 services
Medicare patients, 2024
82
Average age 67
Drug cost, 2024
$8.3M
1,066 prescriptions
Company payments, 2025
$4,691
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Megan M Pearce was code 99214 (office e&m - established), 167 times for 74 patients. In total Megan M Pearce billed 185 services in 3 codes, and Medicare paid $14K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-12-02.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 167 | 74 | $76.80 | $13K |
| 99213 Office E&M - Established | Office | 16 | 13 | $53.11 | $850 |
By year: 2022 $8,182 for 105 services; 2023 $12K for 174 services; 2024 $14K for 185 services.
Medicare prescription drug claims, 2024
In 2024, the drug Megan M Pearce prescribed most often to Medicare patients was Stelara (Ustekinumab), with 221 prescriptions and refills. In total Megan M Pearce wrote 1,066 Medicare prescriptions that cost $8.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Stelara Ustekinumab | 221 | 278 | 40 | $5.9M |
| Diphenoxylate-Atropine Diphenoxylate Hcl/Atropine | 57 | 57 | 20 | $3,543 |
| Rinvoq Upadacitinib | 53 | 57 | 14 | $360K |
| Dicyclomine Hcl Generic | 53 | 68 | 21 | $1,128 |
| Famotidine Generic | 42 | 82 | 15 | $602 |
| Mesalamine Generic | 40 | 85 | 14 | $13K |
| Entyvio Vedolizumab | 40 | 51 | Under 11 | $334K |
| Colestipol Hcl Generic | 39 | 77 | 16 | $7,417 |
| Humira(Cf) Pen Adalimumab | 39 | 44 | Under 11 | $445K |
| Omeprazole Generic | 32 | 79 | 13 | $535 |
| Sodium Chloride 0.9 % Sodium Chloride | 28 | 28 | Under 11 | $46.94 |
| Pantoprazole Sodium Generic | 27 | 61 | 15 | $362 |
| Skyrizi On-Body Risankizumab-Rzaa | 27 | 49 | 11 | $519K |
| Skyrizi Risankizumab-Rzaa | 25 | 25 | Under 11 | $319K |
| Remicade Infliximab | 24 | 34 | Under 11 | $138K |
Brand drugs: 536 claims; generic drugs: - claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Megan M Pearce $4,691 ($4,691 in general payments such as food, travel and fees) from 8 companies. The largest payer was Abbvie Inc. with $2,807.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 33 | $2,807 |
| Celltrion USA Inc. 068270.KS | 10 | $1,128 |
| Janssen Biotech, Inc. JNJ | 19 | $345 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 11 | $226 |
| Janssen Scientific Affairs, LLC JNJ | 2 | $74.98 |
| Lilly USA, LLC LLY | 4 | $67.37 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC BHC | 1 | $24.4 |
| Ardelyx, Inc. ARDX | 1 | $17.82 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.